AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

EVO · NASDAQ · Drug Manufacturers - Specialty & Generic

Evotec (ADR) (EVO)

Combines discovery, development and biologics manufacturing for pharmaceutical and biotechnology partners.

$1.58

After hours+0.01 (+0.64%)

At close$1.57(+1.95%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	225	231	239	209	212	253	229	196	188	287	182	167
Cost of revenue	181	187	199	191	191	201	198	186	188	198	184	169
Gross profit	43	43	40	18	21	53	31	10	0	89	−2	−2
	57	56	61	138	51	45	54	42	51	61	63	58
Research & development	20	10	19	15	14	11	12	9	10	11	12	12
Selling, general & administrative	45	48	53	53	53	57	55	48	48	50	51	46
Other expenses	−8	−2	−11	70	−15	−23	−13	−15	−8	0	0	0
Operating income	−14	−13	−21	−120	−30	8	−23	−32	−51	28	−65	−60
	−20	−14	4	22	−23	−26	−11	−18	2	6	−78	4
Interest income	3	1	2	1	1	0	1	1	1	1	2	0
Interest expense	4	4	3	3	2	5	3	7	3	4	3	3
Other non-operating income	0	11	0	−78	21	21	9	1	−2	−10	75	0
Income before tax	−34	−28	−17	−98	−54	−18	−34	−50	−49	33	−142	−56
Income tax expense	10	−9	7	11	−8	29	2	0	0	17	0	−2
Net income from continuing operations	−45	−18	−24	−109	−45	−47	−36	−50	−49	17	−142	−54
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	−45	−18	−24	−109	−45	−47	−36	−50	−49	17	−142	−54
EPS, basic	−$0.13	−$0.05	−$0.07	−$0.31	−$0.13	−$0.13	−$0.10	−$0.14	−$0.14	$0.05	−$0.40	−$0.15
EPS, diluted	−$0.13	−$0.05	−$0.07	−$0.31	−$0.13	−$0.13	−$0.10	−$0.14	−$0.14	$0.05	−$0.40	−$0.15
Weighted average shares, basic	354	354	355	355	355	349	355	355	355	355	355	356
Weighted average shares, diluted	354	354	355	355	355	355	355	355	355	355	355	356
EBITDA	14	3	−1	−13	−23	−7	−31	−4	−20	65	−111	−31
Depreciation & amortization	28	27	20	28	29	6	0	29	29	27	28	28
EBIT	−14	−24	−21	−41	−52	−13	−31	−33	−49	38	−139	−60